{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T14:47:55Z","timestamp":1784990875422,"version":"3.55.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T00:00:00Z","timestamp":1473206400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2016,12]]},"DOI":"10.1007\/s12185-016-2082-3","type":"journal-article","created":{"date-parts":[[2016,9,7]],"date-time":"2016-09-07T09:08:40Z","timestamp":1473239320000},"page":"669-681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Clinical and pathological aspects of human immunodeficiency virus-associated plasmablastic lymphoma: analysis of 24 cases"],"prefix":"10.1007","volume":"104","author":[{"given":"Yusuke","family":"Koizumi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Uehira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Ota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihiko","family":"Ogawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keishiro","family":"Yajima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Tanuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihoko","family":"Yotsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shotaro","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Ikegaya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitoshi","family":"Minamiguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Hodohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Murotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshige","family":"Mikamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideho","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Ajisawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuma","family":"Shirasaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirokazu","family":"Nagai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshinori","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsunekazu","family":"Hishima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harutaka","family":"Katano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seiji","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,9,7]]},"reference":[{"key":"2082_CR1","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1182\/blood.V89.4.1413","volume":"89","author":"HJ Delecluse","year":"1997","unstructured":"Delecluse HJ, Anagnostopoulos I, Dallenbach F, Hummel M, Marafioti T, Schneider U, et al. Plasmablastic lymphomas of the oral cavity: a new entity associated with the human immunodeficiency virus infection. Blood. 1997;89:1413\u201320.","journal-title":"Blood"},{"key":"2082_CR2","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ajh.21250","volume":"83","author":"J Castillo","year":"2008","unstructured":"Castillo J, Pantanowitz L, Dezube BJ. HIV-associated plasmablastic lymphoma: lessons learned from 112 published cases. Am J Hematol. 2008;83:804\u20139.","journal-title":"Am J Hematol"},{"key":"2082_CR3","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1634\/theoncologist.2009-0304","volume":"15","author":"JJ Castillo","year":"2010","unstructured":"Castillo JJ, Winer ES, Stachurski D, Perez K, Jabbour M, Milani C, et al. Prognostic factors in chemotherapy-treated patients with HIV-associated plasmablastic lymphoma. Oncologist. 2010;15:293\u20139.","journal-title":"Oncologist"},{"key":"2082_CR4","doi-asserted-by":"crossref","first-page":"5270","DOI":"10.1002\/cncr.27551","volume":"118","author":"JJ Castillo","year":"2012","unstructured":"Castillo JJ, Furman M, Beltran BE, Bibas M, Bower M, Chen W, et al. Human immunodeficiency virus-associated plasmablastic lymphoma: poor prognosis in the era of highly active antiretroviral therapy. Cancer. 2012;118:5270\u20137.","journal-title":"Cancer"},{"key":"2082_CR5","doi-asserted-by":"crossref","first-page":"e2014064","DOI":"10.4084\/mjhid.2014.064","volume":"6","author":"M Bibas","year":"2014","unstructured":"Bibas M, Castillo JJ. Current knowledge on HIV-associated plasmablastic lymphoma. Mediterr J Hematol Infect Dis. 2014;6:e2014064.","journal-title":"Mediterr J Hematol Infect Dis"},{"key":"2082_CR6","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1097\/01.pas.0000173023.02724.1f","volume":"29","author":"HY Dong","year":"2005","unstructured":"Dong HY, Scadden DT, de Leval L, Tang Z, Isaacson PG, Harris NL. Plasmablastic lymphoma in HIV-positive patients. An aggressive Epstein\u2013Barr virus-associated extramedullary plasmacytic neoplasm. Am J Surg Pathol. 2005;29:1633\u201341.","journal-title":"Am J Surg Pathol"},{"key":"2082_CR7","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.anndiagpath.2005.07.009","volume":"10","author":"GS Folk","year":"2006","unstructured":"Folk GS, Abbondanzo SL, Childers EL, Foss RD. Plasmablastic lymphoma: a clinicopathologic correlation. Ann Diagn Pathol. 2006;10:8\u201312.","journal-title":"Ann Diagn Pathol"},{"key":"2082_CR8","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1111\/j.1601-0825.2008.01493.x","volume":"15","author":"P Rafaniello Raviele","year":"2009","unstructured":"Rafaniello Raviele P, Pruneri G, Maiorano E. Plasmablastic lymphoma: a review. Oral Dis. 2009;15:38\u201345.","journal-title":"Oral Dis"},{"key":"2082_CR9","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.oraloncology.2009.12.009","volume":"46","author":"SC Sarode","year":"2010","unstructured":"Sarode SC, Sarode GS, Patil A. Plasmablastic lymphoma of the oral cavity: a review. Oral Oncol. 2010;46:146\u201353.","journal-title":"Oral Oncol"},{"key":"2082_CR10","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1093\/jnci\/djr076","volume":"103","author":"MS Shiels","year":"2011","unstructured":"Shiels MS, Pfeiffer RM, Gail MH, Hall HI, Li J, Chaturvedi AK, et al. Cancer burden in the HIV-infected population in the US. J Natl Cancer Inst. 2011;103:753\u201362.","journal-title":"J Natl Cancer Inst"},{"key":"2082_CR11","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1001\/jama.2011.396","volume":"305","author":"MS Shiels","year":"2011","unstructured":"Shiels MS, Pfeiffer RM, Hall HI, Li J, Goedert JJ, Morton LM, et al. Proportions of Kaposi sarcoma, selected non-Hodgkin lymphomas, and cervical cancer in the United States occurring in persons with AIDS, 1980-2007. JAMA. 2011;305:1450\u20139.","journal-title":"JAMA"},{"key":"2082_CR12","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1097\/QAD.0000000000000163","volume":"28","author":"HA Robbins","year":"2014","unstructured":"Robbins HA, Shiels MS, Pfeiffer RM, Engels EA. Epidemiologic contributions to recent cancer trends among HIV-infected people in the US. AIDS. 2014;28:881\u201390.","journal-title":"AIDS"},{"key":"2082_CR13","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1007\/s12185-008-0073-8","volume":"87","author":"H Nagai","year":"2008","unstructured":"Nagai H, Iwasaki N, Odawara T, Okada S. Actual status of AIDS-related lymphoma management in Japan. Int J Hematol. 2008;87:442\u20133.","journal-title":"Int J Hematol"},{"key":"2082_CR14","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1002\/cam4.178","volume":"3","author":"Y Ota","year":"2014","unstructured":"Ota Y, Hishima T, Mochizuki M, Kodama Y, Moritani S, Oyaizu N, et al. Classification of AIDS-related lymphoma cases between 1987 and 2012 in Japan based on the WHO classification of lymphomas, fourth edition. Cancer Med. 2014;3:143\u201353.","journal-title":"Cancer Med"},{"key":"2082_CR15","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1182\/blood.V90.3.1337","volume":"90","author":"A Carbone","year":"1997","unstructured":"Carbone A, Gloghini A, Canzonieri V, Tirelli U. AIDS-related extranodal non-Hodgkin\u2019s lymphomas with plasma cell differentiation. Blood. 1997;90:1337\u20138.","journal-title":"Blood"},{"key":"2082_CR16","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, et al. Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas. J Clin Oncol. 1999;17:1244\u201353.","journal-title":"J Clin Oncol"},{"key":"2082_CR17","doi-asserted-by":"crossref","first-page":"9006","DOI":"10.1073\/pnas.83.23.9006","volume":"83","author":"JG Howe","year":"1986","unstructured":"Howe JG, Steitz JA. Localization of Epstein\u2013Barr virus-encoded small RNAs by in situ hybridizaiton. Proc Nat Acad Sci USA. 1986;83:9006\u201310.","journal-title":"Proc Nat Acad Sci USA"},{"key":"2082_CR18","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1136\/jclinpath-2011-200015","volume":"64","author":"NJ Foot","year":"2011","unstructured":"Foot NJ, Dunn RG, Geoghegan H, Wilkins BS, Neat MJ. Fluorescence in situ hybridisation analysis of formalin-fixed paraffin-embedded tissue sections in the diagnostic work-up of non-Burkitt high grade B-cell non-Hodgkin\u2019s lymphoma: a single centre\u2019s experience. J Clin Pathol. 2011;64:802\u20138.","journal-title":"J Clin Pathol"},{"key":"2082_CR19","unstructured":"Stein H, Harris NL, Campo E. Plasmablastic lymphoma. In: WHO classification of tumors of the hematopoietic and lymphoid tissues, 4th ed. Lyon, France: IARC;2008 2008:P256\u2013257."},{"key":"2082_CR20","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1007\/s00277-008-0601-x","volume":"88","author":"C Ustun","year":"2009","unstructured":"Ustun C, Reid-Nicholson M, Nayak-Kapoor A, Jones-Crawford J, McDonald K, Jillella AP, et al. Plasmablastic lymphoma: CNS involvement, coexistence of other malignancies, possible viral etiology, and dismal outcome. Ann Hematol. 2009;88:351\u20138.","journal-title":"Ann Hematol"},{"key":"2082_CR21","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1080\/10428190290006260","volume":"43","author":"SD Nasta","year":"2002","unstructured":"Nasta SD, Carrum GM, Shahab I, Hanania NA, Udden MM. Regression of a plasmablastic lymphoma in a patient with HIV on highly active antiretroviral therapy. Leuk Lymphoma. 2002;43:423\u20136.","journal-title":"Leuk Lymphoma"},{"key":"2082_CR22","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1080\/10428190410001697395","volume":"45","author":"R Lester","year":"2004","unstructured":"Lester R, Li C, Phillips P, Shenkier TN, Gascoyne RD, Galbraith PF, et al. Improved outcome of human immunodeficiency virus-associated plasmablastic lymphoma of the oral cavity in the era of highly active antiretroviral therapy: a report of two cases. Leuk Lymphoma. 2004;45:1881\u20135.","journal-title":"Leuk Lymphoma"},{"key":"2082_CR23","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1002\/ajh.20807","volume":"82","author":"G Panos","year":"2007","unstructured":"Panos G, Karveli EA, Nikolatou O, Falagas ME. Prolonged survival of an HIV-infected patient with plasmablastic lymphoma of the oral cavity. Am J Hematol. 2007;82:761\u20135.","journal-title":"Am J Hematol"},{"key":"2082_CR24","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/j.1600-0609.2009.01235.x","volume":"82","author":"P Bose","year":"2009","unstructured":"Bose P, Thompson C, Gandhi D, Ghabach B, Ozer H. AIDS-related plasmablastic lymphoma with dramatic, early response to bortezomib. Eur J Haematol. 2009;82:490\u20132.","journal-title":"Eur J Haematol"},{"key":"2082_CR25","doi-asserted-by":"crossref","first-page":"e704","DOI":"10.1200\/JCO.2010.30.0038","volume":"28","author":"M Bibas","year":"2010","unstructured":"Bibas M, Grisetti S, Alba L, Picchi G, Del Nonno F, Antinori A. Patient with HIV-associated plasmablastic lymphoma responding to bortezomib alone and in combination with dexamethasone, gemcitabine, oxaliplatin, cytarabine, and pegfilgrastim chemotherapy and lenalidomide alone. J Clin Oncol. 2010;28:e704\u20138.","journal-title":"J Clin Oncol"},{"key":"2082_CR26","doi-asserted-by":"crossref","first-page":"E43","DOI":"10.3816\/CLML.2010.n.074","volume":"10","author":"M Lipstein","year":"2010","unstructured":"Lipstein M, O\u2019Connor O, Montanari F, Paoluzzi L, Bongero D, Bhagat G. Bortezomib-induced tumor lysis syndrome in a patient with HIV-negative plasmablastic lymphoma. Clin Lymphoma Myeloma Leuk. 2010;10:E43\u20136.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2082_CR27","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hon.2024","volume":"31","author":"CA Dasanu","year":"2013","unstructured":"Dasanu CA, Bauer F, Codreanu I, Padmanabhan P, Rampurwala M. Plasmablastic haemato-lymphoid neoplasm with a complex genetic signature of Burkitt lymphoma responding to bortezomib. Hematol Oncol. 2013;31:164\u20136.","journal-title":"Hematol Oncol"},{"key":"2082_CR28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/ejh.12286","volume":"93","author":"M Yan","year":"2014","unstructured":"Yan M, Dong Z, Zhao F, Chauncey T, Deauna-Limayo D, Wang-Rodriguez J, et al. CD20-positive plasmablastic lymphoma with excellent response to bortezomib combined with rituximab. Eur J Haematol. 2014;93:77\u201380.","journal-title":"Eur J Haematol"},{"key":"2082_CR29","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1111\/bjh.13300","volume":"169","author":"JJ Castillo","year":"2015","unstructured":"Castillo JJ, Reagan JL, Sikov WM, Winer ES. Bortezomib in combination with infusional dose-adjusted EPOCH for the treatment of plasmablastic lymphoma. Br J Haematol. 2015;169:352\u20135.","journal-title":"Br J Haematol"},{"key":"2082_CR30","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1007\/s12185-012-1127-5","volume":"96","author":"M Yotsumoto","year":"2012","unstructured":"Yotsumoto M, Hagiwara S, Ajisawa A, Tanuma J, Uehira T, Nagai H, et al. Clinical characteristics of human immunodeficiency virus-associated Hodgkin lymphoma patients in Japan. Int J Hematol. 2012;96:247\u201353.","journal-title":"Int J Hematol"},{"key":"2082_CR31","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","volume":"124","author":"SM Ansell","year":"2014","unstructured":"Ansell SM. Brentuximab vedotin. Blood. 2014;124:3197\u2013200.","journal-title":"Blood"},{"key":"2082_CR32","doi-asserted-by":"crossref","first-page":"e197","DOI":"10.1200\/JCO.2012.46.9593","volume":"31","author":"BM Holderness","year":"2013","unstructured":"Holderness BM, Malhotra S, Levy NB, Danilov AV. Brentuximab vedotin demonstrates activity in a patient with plasmablastic lymphoma arising from a background of chronic lymphocytic leukemia. J Clin Oncol. 2013;31:e197\u20139.","journal-title":"J Clin Oncol"},{"key":"2082_CR33","doi-asserted-by":"crossref","first-page":"16","DOI":"10.6004\/jnccn.2014.0003","volume":"12","author":"M Gandhi","year":"2014","unstructured":"Gandhi M, Petrich A. Brentuximab vedotin in patients with relapsed HIV-related lymphoma. J Natl Compr Canc Netw. 2014;12:16\u20139.","journal-title":"J Natl Compr Canc Netw"},{"key":"2082_CR34","doi-asserted-by":"crossref","first-page":"14807","DOI":"10.1073\/pnas.0506857102","volume":"102","author":"M Popovic","year":"2005","unstructured":"Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2005;102:14807\u201312.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2082_CR35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","volume":"8","author":"AD Zelenetz","year":"2010","unstructured":"Zelenetz AD, Abramson JS, Advani RH, Andreadis CB, Byrd JC, Czuczman MS, et al. NCCN clinical practice guidelines in oncology: non-Hodgkin\u2019s lymphomas. J Natl Compr Canc Netw. 2010;8:288\u2013334.","journal-title":"J Natl Compr Canc Netw"},{"key":"2082_CR36","doi-asserted-by":"crossref","first-page":"2383","DOI":"10.3109\/10428194.2012.697559","volume":"53","author":"UD Bayraktar","year":"2012","unstructured":"Bayraktar UD, Ramos JC, Petrich A, Gupta N, Lensing S, Moore PC, et al. Outcome of patients with relapsed\/refractory acquired immune deficiency syndrome-related lymphoma diagnosed 1999\u20132008 and treated with curative intent in the AIDS Malignancy Consortium. Leuk Lymphoma. 2012;53:2383\u20139.","journal-title":"Leuk Lymphoma"},{"key":"2082_CR37","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1002\/cncr.26723","volume":"118","author":"SK Barta","year":"2012","unstructured":"Barta SK, Lee JY, Kaplan LD, Noy A, Sparano JA. Pooled analysis of AIDS malignancy consortium trials evaluating rituximab plus CHOP or infusional EPOCH chemotherapy in HIV-associated non-Hodgkin lymphoma. Cancer. 2012;118:3977\u201383.","journal-title":"Cancer"},{"key":"2082_CR38","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1016\/j.leukres.2011.06.023","volume":"35","author":"JJ Liu","year":"2011","unstructured":"Liu JJ, Zhang L, Ayala E, Field T, Ochoa-Bayona JL, Perez L, et al. Human immunodeficiency virus (HIV)-negative plasmablastic lymphoma: a single institutional experience and literature review. Leuk Res. 2011;35:1571\u20137.","journal-title":"Leuk Res"},{"key":"2082_CR39","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1750-9378-8-28","volume":"8","author":"A Friis","year":"2013","unstructured":"Friis A, \u00c5kerlund B, Christensson B, Gyllensten K, Aleman A, Zou JZ, et al. Epstein Barr virus DNA analysis in blood predicts disease progression in a rare case of plasmablastic lymphoma with effusion. Infect Agent Cancer. 2013;8:28.","journal-title":"Infect Agent Cancer"},{"key":"2082_CR40","doi-asserted-by":"crossref","first-page":"8532","DOI":"10.1128\/JVI.77.15.8532-8540.2003","volume":"77","author":"HJ Brown","year":"2003","unstructured":"Brown HJ, Song MJ, Deng H, Wu TT, Cheng G, Sun R. NF-B inhibits gammaherpesvirus lytic replication. J Virol. 2003;77:8532\u201340.","journal-title":"J Virol"},{"key":"2082_CR41","doi-asserted-by":"crossref","first-page":"6297","DOI":"10.1182\/blood-2011-01-332379","volume":"117","author":"CM Shirley","year":"2011","unstructured":"Shirley CM, Chen J, Shamay M, Li H, Zahnow CA, Hayward SD, et al. Bortezomib induction of C\/EBPbeta mediates Epstein\u2013Barr virus lytic activation in Burkitt lymphoma. Blood. 2011;117:6297\u2013303.","journal-title":"Blood"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-016-2082-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-016-2082-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T20:36:58Z","timestamp":1601066218000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-016-2082-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,9,7]]},"references-count":41,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,12]]}},"alternative-id":["2082"],"URL":"https:\/\/doi.org\/10.1007\/s12185-016-2082-3","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,9,7]]}}}